Targeting tumor hypoxia inhibits aggressive phenotype of dedifferentiated thyroid cancer.

Ben MaShishuai WenYi LuoTing-Ting ZhangYichen YangCenkai ShenYan ZhangQinghai JiNing QuYu Wang

Published in: The Journal of clinical endocrinology and metabolism (2022)

Hypoxia score serves as a significant indicator for dedifferentiation status, prognoses and immunotherapeutic response predicted by Tumor Immune Dysfunction and Exclusion in DDTC patients. Targeting hypoxia by ACF is useful to alleviate aggressive phenotype of ATC in pre-clinical model of DDTC.

Keyphrases

endothelial cells
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
cancer therapy
prognostic factors
patient reported outcomes
drug delivery
patient reported